Hypericin and Gossypol have synergistic effects and may be combined with other BH3 mimetics targeting MCL1 or Bcl-xl proteins for combination therapy in PC (Doroshenko et al., 2022). Here, BCL2L1 is linked to pachyonychia congenita.